¾à¸®ÇÐ ¿ë¾î »çÀü
- ÀúÀڱ⺻¿ë¾î»çÀüAI
- ÃâÆÇ»ç(ÁÖ)ÀÛ°¡¿Í
- ÃâÆÇÀÏ2024-09-13
- µî·ÏÀÏ2024-11-25
- SNS°øÀ¯
- ÆÄÀÏÆ÷¸ËEPUB
- ÆÄÀÏÅ©±â306KB
- °ø±Þ»çºÏÅ¥ºê
-
Áö¿ø±â±â
PC
PHONE
TABLET
ÇÁ·Î±×·¥ ¼öµ¿¼³Ä¡
ÀüÀÚÃ¥ ÇÁ·Î±×·¥ ¼öµ¿¼³Ä¡ ¾È³»
¾ÆÀÌÆù, ¾ÆÀÌÆеå, ¾Èµå·ÎÀ̵åÆù, ÅÂºí¸´,
º¸À¯ 3, ´ëÃâ 0,
¿¹¾à 0, ´©Àû´ëÃâ 0, ´©Àû¿¹¾à 0
Ã¥¼Ò°³
? ¿ë¾î»çÀü ½Ã¸®Áî ?´Â °¢ ºÐ¾ßÀÇ ¿ë¾î¸¦ ü°èÀûÀ¸·Î Á¤¸®ÇÏ°í ¼³¸íÇÏ´Â µ¥ ÁßÁ¡À» µÐ Àü¹® »çÀüÀÔ´Ï´Ù. ÀÌ Ã¥Àº ÇØ´ç ºÐ¾ßÀÇ Àü¹®°¡»Ó¸¸ ¾Æ´Ï¶ó Çлý, ¿¬±¸¿ø, ÀÏ¹Ý µ¶ÀÚ ¸ðµÎ¿¡°Ô À¯¿ëÇÑ Âü°í¼°¡ µÉ °ÍÀÔ´Ï´Ù. °¢ ¿ë¾î´Â ¸íÈ®ÇÑ Á¤ÀÇ¿Í ÇÔ²² »ç¿ë ¿¹½Ã, °ü·Ã °³³ä µîÀ» Æ÷ÇÔÇÏ°í ÀÖ¾î, µ¶ÀÚµéÀÌ ¿ë¾îÀÇ Á¤È®ÇÑ ÀÇ¹Ì¿Í ¸Æ¶ôÀ» ½±°Ô ÀÌÇØÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¶ÇÇÑ, ÃÖ½ÅÀÇ Á¤º¸¸¦ ¹Ý¿µÇÏ¿© º¯ÈÇÏ´Â Áö½Ä°ú ±â¼úÀ» Ãæ½ÇÈ÷ ´ã¾Æ³»°í ÀÖ½À´Ï´Ù. ? ¿ë¾î»çÀü ½Ã¸®Áî ?´Â µ¶ÀÚµéÀÌ º¸´Ù ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï °£°áÇÏ°í ¸íÈ®ÇÑ ¼¼ú ¹æ½ÄÀ» äÅÃÇÏ°í ÀÖÀ¸¸ç, À̸¦ ÅëÇØ ´Ù¾çÇÑ ºÐ¾ß¿¡¼ ½ÇÁúÀûÀ¸·Î È°¿ëµÉ ¼ö ÀÖ´Â ½Ç¿ëÀûÀÎ Âü°í¼·Î ÀÚ¸®¸Å±èÇÒ °ÍÀÔ´Ï´Ù. ÀÌ ½Ã¸®Áî´Â µ¶Àڵ鿡°Ô ±íÀÌ ÀÖ´Â ÀÌÇØ¿Í Æø³ÐÀº Áö½ÄÀ» Á¦°øÇÏ¿©, ÇнÀ°ú ¿¬±¸, ½Ç¹«¿¡ ÀÖ¾î ±ÍÁßÇÑ ÀÚ¿øÀÌ µÉ °ÍÀÔ´Ï´Ù.ÀúÀÚ¼Ò°³
±âº»¿ë¾î»çÀüÀº ÇÑ °³ÀÎÀÇ ¿Á¤°ú Çå½ÅÀ¸·Î ź»ýÇÑ ÇÁ·ÎÁ§Æ®ÀÔ´Ï´Ù. ÀÌ ÇÁ·ÎÁ§Æ®ÀÇ ÁÖÀΰøÀº ´Ù¾çÇÑ ºÐ¾ß¿¡¼ ´Ù³â°£ È°µ¿ÇÏ¸ç ½×Àº ¹æ´ëÇÑ Áö½Ä°ú °æÇèÀ» ¹ÙÅÁÀ¸·Î, °¢ ºÐ¾ßÀÇ ¿ë¾î¸¦ ü°èÀûÀ¸·Î Á¤¸®ÇÏ°í Ç¥ÁØÈÇÏ´Â ÀÏÀ» ÁÖµµÇÏ°í ÀÖ½À´Ï´Ù. ±×ÀÇ ºñÀüÀº ¸íÈ®ÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ¿ë¾î»çÀüÀ» ¸¸µé¾î, ±³À°, ¿¬±¸, »ê¾÷ µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼ È°¿ëµÉ ¼ö ÀÖµµ·Ï ÇÏ´Â °ÍÀÔ´Ï´Ù. ÀúÀڴ öÀúÇÑ Á¶»ç¿Í °ËÅä °úÁ¤À» ÅëÇØ Á¤È®ÇÏ°í ÃÖ½ÅÀÇ Á¤º¸¸¦ Á¦°øÇϸç, ÀÌ´Â µ¶Àڵ鿡°Ô Å« ½Å·Ú¸¦ ¾ò°í ÀÖ½À´Ï´Ù. ¾ÕÀ¸·Îµµ ±×´Â Áö½ÄÀÇ °øÀ¯¿Í È®»êÀ» À§ÇØ Áö¼ÓÀûÀ¸·Î ³ë·ÂÇÒ °ÍÀ̸ç, ´Ù¾çÇÑ ºÐ¾ßÀÇ ¿ë¾î »çÀü ½Ã¸®Á ÅëÇØ µ¶Àڵ鿡°Ô À¯ÀÍÇÑ ÀڷḦ Á¦°øÇÏ°íÀÚ ÇÕ´Ï´Ù.¸ñÂ÷
1. ¾àµ¿ÇÐ (Pharmacokinetics)62. ¾à·ÂÇÐ (Pharmacodynamics) 7
3. »ýüÀÌ¿ë·ü (Bioavailability) 8
4. ¹Ý°¨±â (Half-life) 9
5. Ç×»ýÁ¦ (Antibiotic) 10
6. Ç×¾ÏÁ¦ (Antineoplastic) 11
7. ´ë»ç (Metabolism) 12
8. ¼ö¿ëü (Receptor) 13
9. ºÎÀÛ¿ë (Adverse Effect) 14
10. ¿ë·®-¹ÝÀÀ °ü°è (Dose-Response Relationship) 15
11. »ýüÀûÇÕ¼º (Biocompatibility) 16
12. µ¶¼º (Toxicity) 17
13. È¿´É (Efficacy) 18
14. ³»¼º (Tolerance) 19
15. ÀÇÁ¸¼º (Dependence) 20
16. ±Ý´Ü Áõ»ó (Withdrawal Symptoms) 21
17. »óÈ£ÀÛ¿ë (Drug Interaction) 22
18. Èí¼ö (Absorption) 23
19. ºÐÆ÷ (Distribution) 24
20. ´ë»çü (Metabolite) 25
21. È¿·Â (Potency) 26
22. ±æÇ×Á¦ (Antagonist) 27
23. Ç×ü (Antibody) 28
24. È¿¼Ò À¯µµ (Enzyme Induction) 29
25. È¿¼Ò ¾ïÁ¦ (Enzyme Inhibition) 30
26. ¾à¹° ÀúÇ×¼º (Drug Resistance) 31
27. ¾à¹° ¹Ýµ¿ (Rebound Effect) 32
28. ¾à¹° °¨ÀÛ (Sensitization) 33
29. ¾à¹° µ¿¿ªÇÐ (Pharmacokinetics and Pharmacodynamics, PK/PD) 34
30. À¯Àü ¾à¸®ÇÐ (Pharmacogenetics) 35
31. ü³»µ¿·ÂÇÐ (Pharmacokinetics in Body) 36
32. ¾à¹° »óÈ£ÀÛ¿ë (Drug-Drug Interaction) 37
33. Èí¼ö ¼Óµµ (Absorption Rate) 38
34. ´ë»ç °æ·Î (Metabolic Pathway) 39
35. ¿ë·®-¹ÝÀÀ °î¼± (Dose-Response Curve) 40
36. Ä¡·áÁö¼ö (Therapeutic Index) 41
37. ¹Ý°¨±â ¿¬Àå (Half-life Extension) 42
38. ¾à¹° ¿ë·® Á¶Àý (Dose Adjustment) 43
39. ¾à¹° ¹ÝÀÀ (Drug Response) 44
40. ¾à¹° ºÎÀÛ¿ë (Adverse Drug Reaction) 45
41. ¾à¹° ÀÇÁ¸¼º (Drug Dependence) 46
42. ¾à¹° ±Ý´Ü (Drug Withdrawal) 47
43. ¾à¹° »óÈ£ÀÛ¿ë Æò°¡ (Drug Interaction Assessment) 48
44. ¾à¹° Èí¼ö °³¼± (Improvement of Drug Absorption) 49
45. ¾à¹° ´ë»ç Æò°¡ (Drug Metabolism Assessment) 50
46. ¾à¹° ¹è¼³ (Drug Excretion) 51
47. ¾à¹° ³óµµ (Drug Concentration) 52
48. ¾à¹° À¯ÀüÇÐ (Pharmacogenomics) 53
49. ¾à¹° ¼³°è (Drug Design) 54
50. ¾à¹° Àü´Þ ½Ã½ºÅÛ (Drug Delivery System) 55
51. ¾à¹° ¾ÈÀü¼º Æò°¡ (Drug Safety Assessment) 56
52. ¾à¹° È¿°ú (Drug Efficacy) 57
53. ¾à¹° °¨¼ö¼º (Drug Sensitivity) 58
54. ¾à¹° ³»¼º ±âÀü (Mechanism of Drug Resistance) 59
55. ¾à¹° ³²¿ë (Drug Abuse) 60
56. ¾à¹° Áö¼Ó ½Ã°£ (Duration of Drug Action) 61
57. ¾à¹° ¹ÝÀÀ ½Ã°£ (Onset of Drug Action) 62
58. ¾à¹° ³»¼º (Drug Tolerance) 63
59. ¾à¹° ÀÇÁ¸ (Drug Dependence) 64
60. ¾à¹° »óÈ£ÀÛ¿ë ºÐ¼® (Drug Interaction Analysis) 65
61. ¾à¹° Èí¼ö ÃËÁø (Enhancement of Drug Absorption) 66
62. ¾à¹° ´ë»ç ÃËÁø (Enhancement of Drug Metabolism) 67
63. ¾à¹° ¹è¼³ ÃËÁø (Enhancement of Drug Excretion) 68
64. ¾à¹° ÀÛ¿ë ±âÀü (Mechanism of Drug Action) 69
65. ¾à¹° »óÈ£ÀÛ¿ë ¿¹¹æ (Prevention of Drug Interaction) 70
66. ¾à¹° ¿ë·® Á¶Àý ¹æ¹ý (Methods of Dose Adjustment) 71
67. ¾à¹° ¹ÝÀÀ Æò°¡ (Assessment of Drug Response) 72
68. ¾à¹° ºÎÀÛ¿ë ¿¹¹æ (Prevention of Adverse Drug Reactions) 73
69. ¾à¹° ¾ÈÀü¼º ¸ð´ÏÅ͸µ (Drug Safety Monitoring) 74
70. ¾à¹° È¿°ú Æò°¡ (Evaluation of Drug Efficacy) 75
71. ¾à¹° °¨¼ö¼º °Ë»ç (Drug Sensitivity Testing) 76
72. ¾à¹° ³»¼º °Ë»ç (Drug Resistance Testing) 77
73. ¾à¹° ¼³°è ±â¹ý (Techniques of Drug Design) 78
74. ¾à¹° Àü´Þ ±â¹ý (Techniques of Drug Delivery) 79
75. ¾à¹° ¾ÈÀü¼º ½ÃÇè (Drug Safety Testing) 80
76. ¾à¹° È¿°ú ÃøÁ¤ (Measurement of Drug Efficacy) 81
77. ¾à¹° °¨¼ö¼º ¿¹Ãø (Prediction of Drug Sensitivity) 82
78. ¾à¹° ³»¼º ¿¹Ãø (Prediction of Drug Resistance) 83
79. ¾à¹° ¼³°è ¼ÒÇÁÆ®¿þ¾î (Drug Design Software) 84
80. ¾à¹° Àü´Þ ½Ã½ºÅÛ °³¹ß (Development of Drug Delivery Systems) 85
81. ¾à¹° ¾ÈÀü¼º Æò°¡ ±âÁØ (Criteria for Drug Safety Assessment) 86
82. ¾à¹° È¿°ú Æò°¡ ±âÁØ (Criteria for Evaluation of Drug Efficacy) 87
83. ¾à¹° °¨¼ö¼º Æò°¡ ±âÁØ (Criteria for Evaluation of Drug Sensitivity) 88
84. ¾à¹° ³»¼º Æò°¡ ±âÁØ (Criteria for Evaluation of Drug Resistance) 89
85. ¾à¹° ¼³°è ±âÁØ (Criteria for Drug Design) 90
86. ¾à¹° Àü´Þ ½Ã½ºÅÛ Æò°¡ (Evaluation of Drug Delivery Systems) 91
87. ¾à¹° ¾ÈÀü¼º µ¥ÀÌÅÍ (Drug Safety Data) 92
88. ¾à¹° È¿°ú µ¥ÀÌÅÍ (Drug Efficacy Data) 93
89. ¾à¹° °¨¼ö¼º µ¥ÀÌÅÍ (Drug Sensitivity Data) 94
90. ¾à¹° ³»¼º µ¥ÀÌÅÍ (Drug Resistance Data) 95
91. ¾à¹° ¼³°è µ¥ÀÌÅÍ (Drug Design Data) 96
92. ¾à¹° Àü´Þ ½Ã½ºÅÛ µ¥ÀÌÅÍ (Drug Delivery Systems Data) 97
93. ¾à¹° ¾ÈÀü¼º Æò°¡ ÀýÂ÷ (Procedures for Drug Safety Assessment) 98
94. ¾à¹° È¿°ú Æò°¡ ÀýÂ÷ (Procedures for Evaluation of Drug Efficacy) 99
95. ¾à¹° °¨¼ö¼º Æò°¡ ÀýÂ÷ (Procedures for Evaluation of Drug Sensitivity) 100
96. ¾à¹° ³»¼º Æò°¡ ÀýÂ÷ (Procedures for Evaluation of Drug Resistance) 101
97. ¾à¹° ¼³°è ÀýÂ÷ (Procedures for Drug Design) 102
98. ¾à¹° Àü´Þ ½Ã½ºÅÛ ÀýÂ÷ (Procedures for Drug Delivery Systems) 103
99. ¾à¹° ¾ÈÀü¼º ±ÔÁ¦ (Regulations for Drug Safety) 104
100. ¾à¹° È¿°ú ±ÔÁ¦ (Regulations for Drug Efficacy) 105